B · Normal
[The State Food and Drug Administration approves the marketing of rifuxibaizumab injection (subcutaneous injection)] On November 12, the State Food and Drug Administration approved the rifuxibaizumab injection (subcutaneous injection) applied by Beijing Shengdi Pharmaceutical Co., Ltd. through the priority review and approval process (commodity Name: Aqenda) is on the market. This drug can be used in combination with a low-fat diet and other lipid-lowering drugs to treat homozygous familial hypercholesterolemia (HoFH) in adults and adolescents aged 12 years and above to reduce low-density lipoprotein cholesterol (LDL-C) levels. The launch of this variety provides new treatment options for relevant patients.
Comments